BDCA2 antag 
Welcome,         Profile    Billing    Logout  
 1 Company  1 Product   1 Product   0 Diseases   2 Trials   16 News 


123»
  • ||||||||||  Journal:  A focused report on IFN-1 targeted therapies for lupus erythematosus. (Pubmed Central) -  Mar 20, 2025   
    Daxdilimab was unsuccessful in its phase II trial...Anifrolumab binds to the IFN-I receptor, blocking the activity of all IFN-Is, and deucravacitinib reduces IFN-I by inhibiting TYK2, thereby interfering with downstream signaling. Therapies that target IFN-I represents a promising class of medications for SLE patients.
  • ||||||||||  Remicade (infliximab) / J&J
    Biomarker, Journal:  External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn's disease stopping infliximab. (Pubmed Central) -  Nov 13, 2024   
    P3, P4
    This represents the first evidence that cell damage shifts the miRNA content of sEVs towards a TLR7-activating cargo capable to propagate inflammation and immunity, offering strong support to the physiological role of systemic miRNA-based cell-to-cell communication. In patients with CD stopping infliximab, we confirm that the risk of short-term and mid/long-term relapse is associated with distinct blood protein profiles showing the potential to guide infliximab withdrawal.
  • ||||||||||  Review, Journal, Checkpoint inhibition, Checkpoint block:  Inhibitory receptors of plasmacytoid dendritic cells as possible targets for checkpoint blockade in cancer. (Pubmed Central) -  Mar 24, 2024   
    Based on this evidence, we propose that the regulation of IFN secretion by IRs may be regarded as an "innate checkpoint", reminiscent of the function of "classical" adaptive immune checkpoints, like PD1 expressed in CD8+ T cells, which restrain autoimmunity and immunopathology but favor chronic infections and tumors. However, we also point out that further work is needed to fully unravel the biology of tumor-associated pDCs, the neat contribution of pDC exhaustion in tumor growth following the engagement of IRs, especially those expressed also by other leukocytes, and their therapeutic potential as targets of combined immune checkpoint blockade in cancer immunotherapy.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker:  Identification of immunological patterns characterizing immune-related psoriasis reactions in oncological patients in therapy with anti-PD-1 checkpoint inhibitors. (Pubmed Central) -  Mar 22, 2024   
    Here, we investigated the immunological and genetic profiles of two patients with metastatic melanoma and one patient affected by lung cancer, who developed severe psoriasis after receiving anti-PD-1 nivolumab therapy...Our study showed that adaptive immunity predominates over innate immunity in anti-PD-1-induced psoriasis lesions, consistently with the local ADAMTSL5 overexpression. The presence of numerous SNPs in psoriasis susceptibility genes of the three patients also suggested their strong predisposition to the disease.
  • ||||||||||  Altered Cellular Immune Response in the Context of Syphilis and Acute HIV Coinfection (Poster hall) -  Mar 16, 2024 - Abstract #CROI2024CROI_585;    
    The impaired T-cell function, activation, and exhaustion observed in acute HIV/syphilis coinfection result in reduced control of HIV replication. Longitudinal studies of patients coinfected with HIV and syphilis, especially after initiating antiretroviral treatment, are warranted to investigate their effects on the HIV reservoir.
  • ||||||||||  Differentiated monocytes express the pDC markers BDCA-2 and CD123 () -  Feb 25, 2024 - Abstract #LUPUS2024LUPUS_204;    
    Since monocyte subsets are key responder cells to IFN- I, with pathogenic roles in SLE, the efficacy of therapies targeting these markers may be explained by their effects on other myeloid cells and not pDCs. This is important for the safety of these therapies as well as their potential indications beyond the IFN-I mediated diseases.
  • ||||||||||  Dendritic cells subpopulations in smoking induced lung diseases (Exhibit Hall; Poster Board Number: 216) -  Feb 18, 2024 - Abstract #USCAP2024USCAP_2152;    
    Various subtypes of dendritic cells infiltrate the airways in smoking induced lung diseases, pointing to the fact, that inhaled cigarette smoke contains incomplete combusted plant proteins elicitating an influx of antigen presenting cells forcing an immune reaction. The presence of pDC showed that there are some mechanisms acting to downregulate the immune reaction by causing tolerance.
  • ||||||||||  Journal:  Pre-Implant Immune Status is Associated with Infection Risk After Left Ventricular Assist Device Implantation. (Pubmed Central) -  Feb 6, 2024   
    Our results demonstrated that patients with infection in the early post-implant period showed lower concentrations of lymphocytes, especially of CD3+ T cells and CD19+ B cells, decreased percentages of BDCA2+ and BDCA4+ pDCs, and had more often NLRs >7 indicating moderate-to-severe inflammation. Thus, we identified specific immunological changes pre-LVAD that could help to identify patients at risk for infection in the early post-implant period.
  • ||||||||||  Membrane-bound IgE expression on plasmacytoid dendritic cells (pDCs) and B-cells across total serum IgE levels (Monitor 16) -  Sep 14, 2023 - Abstract #ACAAI2023ACAAI_929;    
    Conclusion Overall, this study demonstrates that while pDCs express levels of FcERI that binds IgE, there is no appreciable amount of membrane-bound IgE noted. Additionally, our study also demonstrates that B-cells, more likely CD19 + 27 + , only rarely express membrane-bound IgE in the blood and are presumed to be more commonly found in the bone marrow or lymph nodes.
  • ||||||||||  Review, Journal, IO biomarker:  Targeting Type I Interferon Induction and Signaling: How Zika Virus Escapes from Host Innate Immunity. (Pubmed Central) -  Jul 11, 2023   
    In addition, structural proteins also participate in the innate immune evasion and activation of antibody-binding of blood dendritic cell antigen 2 (BDCA2) or inflammasome also be used to enhance ZIKV replication. In this review, we summarize the recent findings about the interaction between ZIKV infection and type I IFNs pathways and suggest potential strategies for antiviral drug development.
  • ||||||||||  litifilimab (BIIB059) / Biogen
    Review, Journal:  Litifilimab (BIIB059), a promising investigational drug for cutaneous lupus erythematosus. (Pubmed Central) -  Jun 14, 2023   
    P2
    Litifilimab demonstrated efficacy in a randomized phase II clinical trial as a standalone CLE trial using validated skin specific outcome measures, making it the first successful clinical trial for a CLE targeted therapy. If approved, litifilimab will be a pivotal change in the landscape of CLE management especially for severe and refractory disease.
  • ||||||||||  Immunohistological pattern-stratification opens the door for reliabletargeted treatment strategies in cutaneous lupus erythematosus (Ito Hall, University of Tokyo) -  Apr 13, 2023 - Abstract #ISID2023ISID_2364;    
    This study demonstrates that > 90% of CLE patients might be prone to betreated with at least one targeted drug, which were developed for the treatment of SLE oris in clinical studies for CLE. These drugs include belimumab (anti-Blys/ B cells) andanifrolumab (anti-IFNabR), which have already been approved for the treatment of SLEby FDA and EMA, but also anti-pDCs drugs (BIIB059 (anti-BDCA2); Daxdilimab (AntiILT7)) and inhibitors of the JAK/STAT pathway (Tofacitinib (JAK), Lanraplenib &Filgotinib (JAK/SYK), Deucravacitinib (TYK2), which block IFN-mediatedinflammatory pathways.
  • ||||||||||  Characterization of Regulatory Receptors on Plasmacytoid Dendritic Cells in Lupus (Virtual Poster Hall) -  Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_2619;    
    12.83% of pDCs are positive for IFNα. We identify associations between PDC regulatory receptors and clinical disease in lupus patients, and dominant inhibitory function of BDCA2 over ILT7 in pDC type I IFN secretion with dependency upon disease activity